
Pfizer pulls plug on weight-loss pill, citing trial concerns
Investing.com -- Shares of Pfizer Inc (NYSE:PFE) dipped 1.5% as the pharmaceutical giant announced the discontinuation of its drug candidate danuglipron, which was under investigation for chronic weight management.Pfizer said the decision came after a comprehensive review of clinical data and recent regulatory feedback, despite the drug meeting key objectives in earlier studies.The company revea ...